Asitri Dashboard Search Clinical Trials
The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.
Saved Searches
Choose Search
Basic Search
Clinical Trials Search Results
Search History:
Count: 55
Selected: 0
| NCT ID | Title | ||
|---|---|---|---|
| NCT03602157 | Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCL | ||
| NCT02113657 | T-Cell Responses to Neoantigens Post Treatment With Ipilimumab in Men With Metastatic Castration-Resistant Prostate Cancer | ||
| NCT03936465 | Study of the Bromodomain (BRD) and Extra-Terminal Domain (BET) Inhibitors BMS-986158 and BMS-986378 in Pediatric Cancer | ||
| NCT03117920 | A Phase II, International Open Label Trial of Minnelide™ in Patients With Refractory Pancreatic Cancer | ||
| NCT03668431 | Dabrafenib + Trametinib + PDR001 In Colorectal Cancer | ||
| NCT03697239 | High Dose Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin + Gemcitabine (AA NABPLAGEM) in Patients Who Have Metastatic Pancreatic Cancer | ||
| NCT05212025 | Adavosertib and Gemcitabine in Advanced Pancreatic | ||
| NCT03410030 | Trial of Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin + Gemcitabine (AA NABPLAGEM) | ||
| NCT03563248 | Losartan and Nivolumab in Combination With FOLFIRINOX and SBRT in Localized Pancreatic Cancer | ||
| NCT03331562 | A SU2C Catalyst® Trial of a PD1 Inhibitor With or Without a Vitamin D Analog for the Maintenance of Pancreatic Cancer | ||
| NCT01928576 | Phase II Anti-PD1 Epigenetic Therapy Study in NSCLC. | ||
| NCT03682029 | Epigenetics, Vitamin C, and Abnormal Blood Cell Formation - Vitamin C in Patients With Low-Risk Myeloid Malignancies | ||
| NCT05714644 | Community Collaboration to Advance Racial/Ethnic Equity in CRC Screening | ||
| NCT03146962 | High Dose Vitamin C Intravenous Infusion in Patients With Resectable or Metastatic Solid Tumor Malignancies | ||
| NCT03568422 | CFI-402257 in Combination With Paclitaxel in Patients With Advanced/Metastatic HER2-Negative Breast Cancer | ||
| NCT02865135 | Trial To Test Safety And Efficacy Of Vaccination For Incurable HPV 16-Related Oropharyngeal, Cervical And Anal Cancer | ||
| NCT05013216 | Mutant KRAS -Targeted Long Peptide Vaccine for Patients at High Risk of Developing Pancreatic Cancer | ||
| NCT05918640 | Lurbinectedin in FET-Fused Tumors | ||
| NCT03798769 | Supportive Oncology Care at Home for Patients With Pancreatic Cancer Receiving Preoperative FOLFIRINOX | ||
| NCT02775292 | Gene-Modified T Cells, Vaccine Therapy, and Nivolumab in Treating Patients With Stage IV or Locally Advanced Solid Tumors Expressing NY-ESO-1 | ||
| NCT04434040 | Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA) | ||
| NCT03215810 | Nivolumab and Tumor Infiltrating Lymphocytes (TIL) in Advanced Non-Small Cell Lung Cancer | ||
| NCT04261218 | Safety, Pharmacodynamics, Pharmacokinetics, and Efficacy of Tomivosertib Combined With Paclitaxel in Advanced Breast Cancer | ||
| NCT02179970 | To Assess the Safety of Continuous IV Administration of Plerixafor in Patients With Advanced Pancreatic, Ovarian and Colorectal Cancers | ||
| NCT03797443 | High Dose Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin + Gemcitabine (AA NABPLAGEM) in Patients Who Have Metastatic Pancreatic Cancer | ||
| NCT03179943 | Atezolizumab + Guadecitabine in Patients With Checkpoint Inhibitor Refractory or Resistant Urothelial Carcinoma | ||
| NCT03624543 | CFI-400945 in Patients With Advanced/Metastatic Breast Cancer | ||
| NCT03999723 | Combining Active and Passive DNA Hypomethylation | ||
| NCT03092323 | A Randomized Trial of Pembrolizumab & Radiotherapy Versus Radiotherapy in High-Risk Soft Tissue Sarcoma of the Extremity | ||
| NCT04524195 | PET Imaging With [18F]F-AraG in Advanced Non-small Cell Lung Cancer (NSCLC) | ||
| NCT06070870 | Health Education Approach to Lung Screening | ||
| NCT04134884 | Study of ASTX727 Plus Talazoparib in Patients With Triple Negative or Hormone Resistant/HER2-negative Metastatic Breast Cancer | ||
| NCT04995003 | HER2 Chimeric Antigen Receptor (CAR) T Cells in Combination With Checkpoint Blockade in Patients With Advanced Sarcoma | ||
| NCT05995821 | Immunobiology Blood and Tissue Collection of Upper Aerodigestive Malignancies | ||
| NCT03697564 | Nivolumab + Cabiralizumab + Gemcitabine in Patients With Stage IV Pancreatic Cancer Achieving Disease Control in Response to First-line Chemotherapy (GemCaN Trial). | ||
| NCT02048384 | A Study of Metformin With or Without Rapamycin as Maintenance Therapy After Induction Chemotherapy in Subjects With Pancreatic Cancer | ||
| NCT03762590 | GENetic Education Risk Assessment and TEsting Study | ||
| NCT05886764 | Novel Outreach Methods to Increase Enrollment to Early Phase Clinical Trials | ||
| NCT03520790 | Paricalcitol Plus Gemcitabine and Nab-paclitaxel in Metastatic Pancreatic Cancer | ||
| NCT04170959 | The Addition of Metformin to Definitive Radiotherapy in Patients With Stage III NSCLC | ||
| NCT06015659 | ZN-c3 + Gemcitabine in Pancreatic Cancer | ||
| NCT02881242 | Trametinib in Treating Patients With Progressive Metastatic Hormone-Resistant Prostate Cancer | ||
| NCT01088815 | Hedgehog Inhibitors for Metastatic Adenocarcinoma of the Pancreas | ||
| NCT01629615 | A Trial of BKM120 (a PI3K Inhibitor) in Patients With Triple Negative Metastatic Breast Cancer | ||
| NCT04469556 | Pancreatic Adenocarcinoma Signature Stratification for Treatment | ||
| NCT03566485 | Atezolizumab and Cobimetinib or Idasanutlin in Participants With Stage IV or Unresectable Recurrent Estrogen Receptor Positive Breast Cancer | ||
| NCT02719977 | A Phase I Study of CX5461 | ||
| NCT03220477 | Pembrolizumab (Immunotherapy Drug) in Combination With Guadecitabine and Mocetinostat (Epigenetic Drugs) for Patients With Advanced Lung Cancer. | ||
| NCT03803553 | Identification and Treatment Of Micrometastatic Disease in Stage III Colon Cancer | ||
| NCT04262154 | Study of Abiraterone Acetate or Enzalutamide, Atezolizumab, GnRH Analog and Radiation Therapy in Men With Newly Diagnosed Hormone-sensitive Prostate Cancer |
